Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Inventory Average (2021 - 2025)

Historic Inventory Average for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $44.8 million.

  • Kiniksa Pharmaceuticals International's Inventory Average rose 4098.18% to $44.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.8 million, marking a year-over-year increase of 4098.18%. This contributed to the annual value of $28.7 million for FY2024, which is 903.81% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Inventory Average stood at $44.8 million for Q3 2025, which was up 4098.18% from $35.1 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Inventory Average registered a high of $44.8 million during Q3 2025, and its lowest value of $4.3 million during Q2 2021.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's median Inventory Average value was $24.0 million (recorded in 2023), while the average stood at $22.1 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Inventory Average skyrocketed by 29025.97% in 2022 and then tumbled by 1706.68% in 2025.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Inventory Average stood at $4.6 million in 2021, then soared by 290.26% to $18.1 million in 2022, then soared by 56.56% to $28.4 million in 2023, then fell by 2.93% to $27.5 million in 2024, then soared by 62.74% to $44.8 million in 2025.
  • Its last three reported values are $44.8 million in Q3 2025, $35.1 million for Q2 2025, and $24.2 million during Q1 2025.